Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124644 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00124644 is a Phase 1 study that was terminated before completion, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 30 participants.
The verdict
NCT00124644, a Phase 1 study, was terminated before completion, sponsored by Ohio State University Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cytarabine, daunorubicin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with tipifarnib may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when given together with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia.
Interventions
- DRUG etoposide
- DRUG cytarabine
- DRUG tipifarnib
- DRUG daunorubicin hydrochloride
- PROCEDURE chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00124644
The ClinicalTrials.gov registry entry for NCT00124644 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which etoposide is the first listed.
NCT00124644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00124644 about?
NCT00124644 is a clinical study titled "Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as cytarabine, daunorubicin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for ...
What is the current status of trial NCT00124644?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2006-03. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00124644?
The interventions under investigation include: etoposide (DRUG), cytarabine (DRUG), tipifarnib (DRUG), daunorubicin hydrochloride (DRUG), chemotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT00124644?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.